[go: up one dir, main page]

NZ737605A - Synthetic lethality and treatment of cancer - Google Patents

Synthetic lethality and treatment of cancer

Info

Publication number
NZ737605A
NZ737605A NZ737605A NZ73760512A NZ737605A NZ 737605 A NZ737605 A NZ 737605A NZ 737605 A NZ737605 A NZ 737605A NZ 73760512 A NZ73760512 A NZ 73760512A NZ 737605 A NZ737605 A NZ 737605A
Authority
NZ
New Zealand
Prior art keywords
nmt2
cancer
treatment
nmt1
inhibitor
Prior art date
Application number
NZ737605A
Inventor
Luc Berthiaume
Erwan Beauchamp
Conganige Maneka Anne Perinpanayagam
Chuiyee Yap
Original Assignee
Pacylex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacylex Pharmaceuticals Inc filed Critical Pacylex Pharmaceuticals Inc
Publication of NZ737605A publication Critical patent/NZ737605A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed is a use of an N-myristoyltransferase 1 (NMT1) inhibitor for the preparation of a medicament for treating a subject having Burkitt’s lymphoma deficient in NMT2 by determining epigenetic inactivation in an NMT2 gene or loss of protein function or having a level of NMT2 protein that is low or absent compared to a control normal B cell. The NMT1 inhibitor can be a small molecule, antibody, peptide fragment or nucleic acid and may be administered with a chemotherapeutic agent.
NZ737605A 2011-07-22 2012-07-23 Synthetic lethality and treatment of cancer NZ737605A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161510686P 2011-07-22 2011-07-22
NZ72044112 2012-07-23

Publications (1)

Publication Number Publication Date
NZ737605A true NZ737605A (en) 2022-11-25

Family

ID=84527767

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ737605A NZ737605A (en) 2011-07-22 2012-07-23 Synthetic lethality and treatment of cancer

Country Status (1)

Country Link
NZ (1) NZ737605A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12343341B2 (en) 2011-07-22 2025-07-01 Pacylex Pharmaceuticals Inc. Synthetic lethality and the treatment of cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12343341B2 (en) 2011-07-22 2025-07-01 Pacylex Pharmaceuticals Inc. Synthetic lethality and the treatment of cancer

Similar Documents

Publication Publication Date Title
Castello et al. Osteopontin at the crossroads of inflammation and tumor progression
Kelly et al. Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase
Liu et al. miR-451 acts as a suppressor of angiogenesis in hepatocellular carcinoma by targeting the IL-6R-STAT3 pathway
Xu et al. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity
Weingart et al. Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target
Shagisultanova et al. Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases
Tian et al. MicroRNA-429 inhibits the migration and invasion of colon cancer cells by targeting PAK6/cofilin signaling
Monma et al. Chloroquine augments TRAIL-induced apoptosis and induces G2/M phase arrest in human pancreatic cancer cells
WO2015031771A3 (en) Administration of kynurenine depleting enzymes for tumor therapy
Zhai et al. Bufalin reverses resistance to sorafenib by inhibiting Akt activation in hepatocellular carcinoma: the role of endoplasmic reticulum stress
EA201491584A1 (en) METHODS OF TREATING NON-SMALL-CELL LUNG CANCER WITH THE USE OF COMBINED TREATMENT WITH KINASE TOR INHIBITOR
EA201500826A1 (en) CONTAINING ALBUMINS-BINDING ARGININESYMINASE PHARMACEUTICAL COMPOSITION FOR TARGETIC CANCER THERAPY
NZ626867A (en) Compositions and methods for the treatment of infections and tumors
Zhao et al. Long non-coding RNA SNHG20 promotes bladder cancer via activating the Wnt/β-catenin signalling pathway
Kunze et al. Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells
MY169532A (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
Salguero-Aranda et al. STAT6 knockdown using multiple siRNA sequences inhibits proliferation and induces apoptosis of human colorectal and breast cancer cell lines
Xia et al. Increased miR-203-3p and reduced miR-21-5p synergistically inhibit proliferation, migration, and invasion in esophageal cancer cells
EA201401353A1 (en) BIOMARKERS TO DETERMINE AN EFFECTIVE RESPONSE RESPONSE TO THE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)
NZ594950A (en) Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
BR112014016723A2 (en) method for treating breast cancer
Zhao et al. Olaparib and enzalutamide synergistically suppress HCC progression via the AR‐mediated miR‐146a‐5p/BRCA1 signaling
Wang et al. Downregulation of miR-486-5p enhances the anti-tumor effect of 5-fluorouracil on pancreatic cancer cells
NZ737605A (en) Synthetic lethality and treatment of cancer
US9546366B2 (en) Replication factor C-40 (RFC40/RFC2) as a prognostic marker and target in estrogen positive and negative and triple negative breast cancer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 9 YEARS UNTIL 23 JUL 2025 BY WRAYS PTY LTD

Effective date: 20230531

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JUL 2026 BY CLARIVATE IP SERVICES LIMITED

Effective date: 20250702